– USA, CA – California based myoscience, inc., developers of the ioveraº® product powered by Focused Cold TherapyTM for the treatment of peripheral nerve conditions, announced today Jim Hawkins has joined its Board of Directors.
“We are very fortunate to welcome Jim to our Board of Directors. Jim is an experienced medical technology veteran who has built many successful businesses,” said Clint Carnell, Chairman and Chief Executive Officer of myoscience. “Jim will be a valuable resource to the Company, and to me personally, as we continue to grow and scale our business.”
“I am delighted to join myoscience and look forward to working closely with the board and the management team to further the Company’s achievements of its innovative ioveraº system,” said Jim Hawkins. Mr. Hawkins has served as Chief Executive Officer and a member of the Board of Directors of Natus Medical Incorporated (Nasdaq:BABY) since April 2004. In addition, he currently serves as a director of Digirad Corporation and IRIDEX Corporation. Prior to joining Natus, Mr. Hawkins was President, Chief Executive Officer and a Director of Invivo Corporation, a developer and manufacturer of multi-parameter vital sign monitoring equipment.
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the technology underlying the ioveraº treatment, which is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.